Results-All patients experienced rapid symptomatic relief and, in three cases, complete palliation was achieved during survival times of seven weeks, nine weeks, and 24 weeks, respectively. Two survivng patients (with a recurrent thymoma and fibrosing mediastinitis) were free of symptoms when followed up at eight and nine months respectively. Conclusions-Initial experience with the Wallstent endoprosthesis suggests that it is a valuable treatment alternative once conventional therapy has failed and gives rapid relief of symptoms to patients with obstruction of the superior vena cava. (Thorax 1993;48:915-920) 
Obstruction of the superior vena cava is a distressing condition characterised by considerable facial and arm swelling, shortness of breath, and intractable headaches; these latter two symptoms are often aggravated by certain postures such as stooping or lying flat. It is a frequent accompaniment to advanced mediastinal malignancy and traditional treatment relies on radiotherapy, chemotherapy, or surgery.l4 Radiotherapy and chemotherapy for malignant causes of obstruction of the superior vena cava may produce an initial improvement, but symptoms often recur with subsequent resistance to further treatment. Surgical management is associated with high morbidity and mortality in patients with an already short life expectancy. Percutaneous intravenous stent placement for the treatment of obstruction of the superior vena cava has previously been reported with the Gianturco stent"9 and the Palmaz stent.'0 The self expanding metallic Wallstent has been used in arterial and hepatobiliary work" 12 and in two cases of malignant obstruction of the superior vena cava. 13 We present our initial experience with the Wallstent in five patients with the condition: four due to malignancy and one due to fibrosing mediastinitis.
Method
Approval from the hospital ethics committee was obtained and informed consent was given by each patient.
All patients had a digital subtraction superior vena cavogram ( fig 1A) via a right femoral vein approach to: (1) exclude intraluminal thrombus or tumour, (2) confirm the length and severity of the stricture, and (3) identify the site of obstruction with respect to the right atrium and confluence of brachiocephalic veins. A 7 Fr straight flush catheter and a 0-038 inch diameter guidewire introduced through a 9 Fr introducer sheath (Cordis Corporation, Miami, Florida) were used to traverse the stricture. Balloon angioplasty of the stricture was then performed ( fig  1B) . The diameter of the balloon varied from 10 to 14 mm (Olbert, Meadox Surgimed A/S Stenlose, Denmark or Meditech, Watertown, South Africa) and a variable degree of dilatation was achieved (ranging from 50% to 100% of the fully inflated balloon diameter). A preloaded (9 Fr) Wallstent endoprosthesis (approximate cost £600) of appropriate length (44-77 mm) and expanded diameter (14-16 mm) was then positioned across the stricture and released from its restraining sheath ( fig 1C) . As the Wallstent expands from its sheath there is a corresponding reduction in length of 20-40%. Careful evaluation with fluoroscopy is required to ensure that the centre of the stent lies across the area of maximum stenosis. After placement a firther cavogram was performed to confirm patency and free flow into the right atrium and pulmonary circulation ( fig 1D) . All patients were anticoagulated with intravenous heparin (24 000 units/24 hours) for 72 hours and received 75 mg aspirin daily thereafter. A chest radiograph was taken after the procedure to show the position and state of expansion of the stent to assist in follow up ( fig  1E) . 1B) and a Wallstent, 77 mm long and 14 mm in diameter, was positioned across the stricture (fig 1 C) . A good haemodynamic result was achieved with rapid flow through the superior vena cava into the pulmonary circulation ( fig 1D) . The patient had immediate and total symptomatic relief. A chest radiograph performed after the procedure confirmed the position of the stent, and another chest radiograph one month later showed some further expansion of the stent at the site of the stricture (fig 1E) from within the stent (fig 2B) . This was extremely difficult and the patient experienced pain during expansion of the balloon; only 50% dilatation was achieved. A cavogram performed after the procedure confirmed patency of the superior vena cava and good flow into the pulmonary circulation. The patient experienced rapid relief of her symptoms and after 72 hours all arm and facial oedema had resolved. The patient died nine weeks later without recurrence of symptoms of superior vena cava obstruction. CASE 5 A 55 year old man was thought to have malignant mediastinal disease at presentation in 1979 and received radiotherapy. Surgical biopsy at that time did not confirm malignancy and the diagnosis was subsequently revised to fibrosing mediastinitis secondary to granulomatous disease, probably tuberculosis. He had symptoms of obstruction of the superior vena cava for the five years before presenting in May 1992, but these had become significantly worse in the preceding six months. A computed tomographic scan at this time showed extensive upper lobe fibrosis and calcific foci as well as heavily calcified enlarged lymph nodes in the superior mediastinum ( fig 3A) . Cavography demonstrated a stricture in the mid superior vena cava ( fig 3B) . Balloon angioplasty with an Olbert catheter, 4 cm long The results of treatment of obstruction of the superior vena cava with self expanding metallic stents have been more favourable, both with the expandable Gianturco stent5-9 and with the balloon expandable Palmaz stent.'0 The successful palliation of obstruction with the Gianturco stent has been reported in six cases of restenosis of malignant obstruction of the superior vena cava following maximum tolerance radiotherapy.5 In two of these obstruction was associated with massive thrombosis which was successfully treated by fibrinolysis before stent placement. A larger multicentre study8 documented successful palliation in 17 patients with malignant obstruction of the superior vena cava, with most of the patients having metastatic carcinoma of the lung and surviving between a few days and several months. There were two long term survivors (thymoma 26 months, lymphoma 18 months). The only complication after stent insertion in this group of patients was a transient phrenic nerve palsy in a patient with bronchial carcinoma treated by radiotherapy. The postulated cause for this was compression of the phrenic nerve against surrounding tumour and radiation fibrosis during balloon angioplasty, rather than damage from the stent.
Quinn et al9 reported the use of the Gianturco stent in four patients with obstruction of the superior vena cava with a 50% occlusion rate three months later. The early occlusion rate is attributed to the rigidity of the Gianturco stent and its use at major venous confluences and areas of vascular curvature.
Solomon et al "0 reported a series of six patients with obstruction of the superior vena cava, one of whom was treated with a Gianturco self expanding stent and five with a Palmaz balloon expandable stent. There was complete resolution of symptoms (within one to three days) in five cases, with partial improvement in the remaining patient who had persistent oedema of the head and neck. Two cases had recurrence of symptoms at a later date, however; one had rethrombosis treated by percutaneous thrombectomy and angioplasty on two occasions (at six and 10 weeks), and the other developed a further stenosis secondary to tumour progression just distal to the stent which was successfully treated by angioplasty. As the balloon expandable Palmaz stent does not have any intrinsic radial expansile force, unlike the Gianturco stent or Wallstent, the maximum achievable diameter of the lumen will be seen immediately after angioplasty.
The self expanding Wallstent metallic prosthesis already has an established role in the treatment of malignant obstruction of the biliary tree'2 and in peripheral and coronary arteries resistant to angioplasty." The success of the Wallstent in these applications has led to its increasing use in other clinical areas, such as in obstruction of the urinary tract'6 and the superior vena cava."1 In the series reported by Antonucci et al 13 two patients with bronchial carcinoma were treated for obstruction of the superior vena cava. In one patient the stent remained patent until death six weeks later, but in the other patient the stent occluded after three days. This was successfully recanalised with thrombolysis and angioplasty but occluded again after eight weeks. In our series immediate relief of symptoms in all five patients was achieved with no evidence of early or late thrombosis or stent occlusion. In four of the five cases we performed angioplasty before the placement of the stent, and we regard this as an important part of the procedure even when full dilatation is not achieved. In three cases no premedication was given, but one patient (case 4) experienced discomfort on inflation of the angioplasty balloon which resolved when the balloon was deflated. As a result we now routinely prescribe premedication of 2-5 mg midazolam orally before the procedure. A definite contraindication to stent placement within the superior vena cava is the presence of intraluminal tumour 
